TBG Diagnostics Value Stock - Dividend - Research Selection
Fundamental data and company key figures of the share
|Annual reports in|
|Net operating cash flow|
|Free cash flow|
|Liabilities & Shareholders equity|
|Diluted shares outstanding|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Raw Data Source|
Description of the company
TBG Diagnostics Limited, formerly Progen Pharmaceuticals Limited, is a biotechnology company. The Company's principal activities include the discovery, research and development of pharmaceutical therapeutics for the treatment of human diseases and the provision of contract services related to process development, manufacturing and quality assurance of biopharmaceutical products. The segments of the company include research and development as well as manufacturing. The company is primarily engaged in the discovery and development of small molecule cancer therapeutics. The company focuses on the development of the anti-angiogenesis and anti-metastasis products pipeline. The company's offer includes Muparfostat (PI-88) and PG545. Muparfostat (PI-88) is an anti-angiogenic and antimetastatic compound. Muparfostat (PI-88) is a dual angiogenesis and heparanase inhibitor. PG545 is an agent that targets the tumor microenvironment.